Penack, Olaf; Peczynski, Christophe; Koenecke, Christian; Polge, Emmanuelle; Sanderson, Robin; Yakoub-Agha, Ibrahim; Fegueux, Nathalie; Daskalakis, Michael; Collin, Matthew; Dreger, Peter; Kröger, Nicolaus; Schanz, Urs; Bloor, Adrian; Ganser, Arnold; Besley, Caroline; Wulf, Gerald G; Novak, Urban; Moiseev, Ivan; Schoemans, Hélène; Basak, Grzegorz W; ... (2023). Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. Frontiers in immunology, 14, p. 1252811. Frontiers Research Foundation 10.3389/fimmu.2023.1252811
|
Text
fimmu-14-1252811.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (585kB) | Preview |
We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology 04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory |
UniBE Contributor: |
Daskalakis, Michael, Novak, Urban |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1664-3224 |
Publisher: |
Frontiers Research Foundation |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
16 Oct 2023 12:38 |
Last Modified: |
03 Dec 2023 02:29 |
Publisher DOI: |
10.3389/fimmu.2023.1252811 |
PubMed ID: |
37828980 |
Uncontrolled Keywords: |
CAR T-cell CD19 large B-cell lymphoma organ complications toxicity |
BORIS DOI: |
10.48350/187164 |
URI: |
https://boris.unibe.ch/id/eprint/187164 |
Actions (login required)
 |
Edit item |